Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 768, Issue -, Pages 28-40Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2015.10.003
Keywords
Synergy; Cucurbitacin B; Curcumin; Enhancing apoptosis induction; Reversing multidrug resistance
Categories
Funding
- Science and Technology Ministry of China [2009ZX09102-113]
- Science and Technology Department of Liaoning province [2013022064]
Ask authors/readers for more resources
Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma. Curcumin, isolated from a plant Curcuma longa also has found the antitumor property. In the present study, the synergistic effect of cucurbitacin B and curcumin was studied on BEL7402/5-Fu cells in vitro and BEL7402 tumor-bearing mice in vivo. The synergistic anticancer activity of these two compounds involves the two mechanisms. Firstly, curcumin synergistically enhanced the apoptosis of BEL7402/5-Fu cells induced by cucurbitacin B in the optimal mass ratio of 2:1 (cucurbitacin B:curcumin). The mechanism may result from the cell arresting in different phases of cell cycles and the apoptotic change of ultrastructure in BEL7402/5-Fu cells. Secondly, curcumin reversed the multidrug resistance (MDR) caused by cucurbitacin B in the optimized concentration of 67.9 mu M (25 mu g/ml). The mechanism was associated with the P-gp reduction, Delta Psi(m) collapse and mitochondrial colocalization in BEL7402/5-Fu cells. The findings were consistent with the changes of the body weight and tumor volume, caspase3 activation and ATP down-regulation in vivo. In conclusion, cucurbitacin B in the combination with curcumin could serve as a novel, promising approach for human hepatoma. (C) 2015 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available